06/03/13

Another blow for microbicide HIV prevention

Young women need more appropriate HIV prevention methods Copyright: Flickr/World Bank Photo Collection

By: Esther Nakkazi

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Another blow for microbicide HIV prevention</h1>
<h4>By: Esther Nakkazi</h4>
</div>
<br />
<br />

<div id="article-body">
<p><span>[KAMPALA] A large-scale trial to compare the effectiveness of oral tablets and vaginal gels for <a href="http://www.scidev.net/en/health/hiv-aids/">HIV</a> prevention among young, unmarried African women has yielded disappointing results, a study reports.</span></p>
<p>Most trial participants failed to follow guidelines for using the products — Truvada gel and Tenofovir tablets that must be applied or taken daily — which led researchers to conclude that, despite being safe, the products are not effective for this group.</p>
<p><span> </span></p>
<p>"No intervention is going to be effective unless it’s used," says Zvavahera Chirenje, one of the study’s lead authors and a researcher at the University of Zimbabwe in Harare. "The majority of participating women did not use any of the study products as recommended."</p>
<div style="margin: 0pt 10px 10px 0pt; background: #ededed; width: 50%; float: left;" class="box">
<div class="inherit_box box">
<h3 style="color: #ffffff; margin: 0px;">SPEED READ</h3>
</div>
<div>
<ul style="list-style: disc outside; margin: 10px 5px 10px 20px;">
<li style="padding: 0 0 5px;">Two-thirds of trial participants failed to follow guidelines</li>
<li style="padding: 0 0 5px;">Researchers suspect hectic lifestyles and poor awareness of at-risk status curtail product use</li>
<li style="padding: 0 0 5px;">This ‘very high risk’ group urgently needs ‘safe, effective and practical HIV prevention methods’</li>
</ul>
</div>
</div>
<p><span>Previous studies on some <a href="http://www.scidev.net/en/health/hiv-aids/news/a-blow-to-promising-hiv-microbicide-gel.html">microbicide gels have also shown little effectiveness</a>.</span></p>
<p><span>The three-year study, the Vaginal and Oral Interventions to Control the Epidemic (VOICE), was a major HIV prevention trial to test whether Truvada and Tenofovir are effective in preventing sexual transmission of HIV in women. </span></p>
<p><span>It was carried out in South Africa, Uganda and Zimbabwe, and involved more than 5,000 participants — about a half of them under 25 years old and 80 per cent unmarried.</span></p>
<p>"We do not know why most of these young women at <span>high risk [of infection] did not use the trial products to prevent HIV," says Clemensia Nakabiito, principal investigator for the Makerere University-Johns Hopkins University Research Collaboration (MUJHU), which focuses on HIV prevention. </span></p>
<p>"We suspect that the youngsters’ hectic lifestyles, lack of time, and disregarding of the fact that they are high risk can be blamed for the low adherence," she adds.</p>
<p><span>Teopista Nakyanzi, MUJHU community coordinator, tells <em>SciDev.Net</em> that older, married women who have extra-marital sex are more inclined to consider themselves high risk and to protect themselves than younger women. Women account for 60 per cent of adults living with HIV in <a href="http://www.scidev.net/en/sub-suharan-africa/">Sub-Saharan Africa</a>.</span></p>
<p><span>Laboratory tests detected <a href="http://www.scidev.net/en/health/drug-development/">drugs</a> in less than a third of blood samples from women who were assigned to use either tablets or gel, and in less than a quarter of samples from women designated to use gel. </span></p>
<p>"These were very low rates, [preventing us] determining whether products were effective in those who used [methods] consistently," says Chirenje.</p>
<p><span>Researchers suggest that HIV prevention products that require minimal adherence may be more suitable for young unmarried women. Conversely, they say daily prevention programmes are more suitable for couples with one HIV positive partner and homosexual men. </span></p>
<p><span>Two ongoing trials — ASPIRE and the Ring Study — are evaluating a vaginal ring that releases an antiretroviral drug over a month period. </span></p>
<p>Due to low adherence rates, "we need to emphasise combination prevention", says Jeanne Marrazzo, professor of medicine at the University of Washington in Seattle, United States.</p>
<p><span>"This group of young <a href="http://www.scidev.net/en/science-and-innovation-policy/gender/">women</a> remains at very high risk of HIV infection, and urgently needs safe, effective and practical HIV prevention methods that they will actually use," she adds.</span></p>
<p><a href="http://www.mtnstopshiv.org/node/4877">Link to study results announcement</a></p>
<p><em><span>This article has been produced by SciDev.Net’s Sub-Saharan Africa desk.</span></em></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/sub-saharan-africa/news/another-blow-for-microbicide-hiv-prevention-6/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/sub-saharan-africa/news/another-blow-for-microbicide-hiv-prevention-6/",null,true])
</script>
</div>

[KAMPALA] A large-scale trial to compare the effectiveness of oral tablets and vaginal gels for HIV prevention among young, unmarried African women has yielded disappointing results, a study reports.

Most trial participants failed to follow guidelines for using the products — Truvada gel and Tenofovir tablets that must be applied or taken daily — which led researchers to conclude that, despite being safe, the products are not effective for this group.

"No intervention is going to be effective unless it’s used," says Zvavahera Chirenje, one of the study’s lead authors and a researcher at the University of Zimbabwe in Harare. "The majority of participating women did not use any of the study products as recommended."

SPEED READ

Two-thirds of trial participants failed to follow guidelines
Researchers suspect hectic lifestyles and poor awareness of at-risk status curtail product use
This ‘very high risk’ group urgently needs ‘safe, effective and practical HIV prevention methods’

Previous studies on some microbicide gels have also shown little effectiveness.

The three-year study, the Vaginal and Oral Interventions to Control the Epidemic (VOICE), was a major HIV prevention trial to test whether Truvada and Tenofovir are effective in preventing sexual transmission of HIV in women.

It was carried out in South Africa, Uganda and Zimbabwe, and involved more than 5,000 participants — about a half of them under 25 years old and 80 per cent unmarried.

"We do not know why most of these young women at high risk [of infection] did not use the trial products to prevent HIV," says Clemensia Nakabiito, principal investigator for the Makerere University-Johns Hopkins University Research Collaboration (MUJHU), which focuses on HIV prevention.

"We suspect that the youngsters’ hectic lifestyles, lack of time, and disregarding of the fact that they are high risk can be blamed for the low adherence," she adds.

Teopista Nakyanzi, MUJHU community coordinator, tells SciDev.Net that older, married women who have extra-marital sex are more inclined to consider themselves high risk and to protect themselves than younger women. Women account for 60 per cent of adults living with HIV in Sub-Saharan Africa.

Laboratory tests detected drugs in less than a third of blood samples from women who were assigned to use either tablets or gel, and in less than a quarter of samples from women designated to use gel.

"These were very low rates, [preventing us] determining whether products were effective in those who used [methods] consistently," says Chirenje.

Researchers suggest that HIV prevention products that require minimal adherence may be more suitable for young unmarried women. Conversely, they say daily prevention programmes are more suitable for couples with one HIV positive partner and homosexual men.

Two ongoing trials — ASPIRE and the Ring Study — are evaluating a vaginal ring that releases an antiretroviral drug over a month period.

Due to low adherence rates, "we need to emphasise combination prevention", says Jeanne Marrazzo, professor of medicine at the University of Washington in Seattle, United States.

"This group of young women remains at very high risk of HIV infection, and urgently needs safe, effective and practical HIV prevention methods that they will actually use," she adds.

Link to study results announcement

This article has been produced by SciDev.Net’s Sub-Saharan Africa desk.